Register
Login:
Share:
Email Facebook Twitter


London South East Natural Resources Briefing webcast: #Emmerson #Alba #Condor Gold #Gold analysis
Angus Energy in talks to buy 'transformational' gas asset in North England


Angle Share Chat (AGL)



Share Price: 68.80Bid: 68.00Ask: 69.60Change: 3.10 (+4.72%)Riser - Angle
Spread: 1.60Spread as %: 2.35%Open: 65.70High: 69.00Low: 65.70Yesterday’s Close: 65.70


Share Discussion for Angle




View all AGL Messages

Please login or register to post a message on Share Chat.

Posts per page:

Drums
Posts: 202
Opinion:No Opinion
Price:74.50
RE: FDA
19 Apr '19
I follow the Angle conversations on two sites, here and ADVFN. Putting aside my opinion that on the latter they do tend to overthink things a bit at times.The treads on both over the last week have been exactly what I have been waiting to hear. Sensible people coming to sensible conclusions based on long term knowledge and research.
Bottom line .... Now is not the time to sell.
GLA but especially to us long term sufferers Sorry, I mean holders.
 
Jelenko
Posts: 99
Opinion:No Opinion
Price:74.50
RE: FDA
19 Apr '19
We will not be briefed on the MBC trial results until the FDA have made a decision. This is because the study is for the FDA and they will have to be briefed first in the form of FDA application submission. Most people that are familiar with the product know it will deliver, it always has, we know it can capture and harvest CTC's.
Regarding the broker sp. target, it's been that for yonks. Never changes on any news. it's useless and so are Finncap(in my view)
The sp. is likely to move forward for many reasons but I feel that we will be well over £1 before FDA announcement and that on the day of the RNS we will double at least.
Lostinfrance
Posts: 237
Opinion:No Opinion
Price:74.50
FDA
19 Apr '19
The breast Cancer study is due to report in the coming months and put in the application for FDA approval in summer. This is what was reported earlier this year. Downstream analyses of the samples will now be completed by the centres and the evaluation of the results from the clinical study and the ongoing analytical studies will be completed with the aim of a submission to the FDA mid-year, as planned. The timing of FDA regulatory clearance is dependent on the FDA's review and response to our submission.
I can only see the share price rising for the trial results, and if all is good ,( which it has been with every trial up to press as far as I have seen) it will make a new high. Then await the creep up on FDA acceptance of the dossier and hopefully Acceptance for approval. After Mtfb falling the other month I’m keeping my fingers crossed.




Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk









Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.